Posts by: Patricia Inacio, PhD

News

New computer software is able to identify targets for potential immunotherapies in individual leukemia patients undergoing stem cell transplants, a new study shows. These results open the door for tailored ... Read more

August 21, 2018August 21, 2018

FDA Approves Opdivo for Certain Patients with Advanced Non-Small Cell Lung Cancer

News

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) to treat patients with metastatic small cell lung cancer (SCLC) who failed to respond to platinum-based chemotherapy and at least one ... Read more

July 20, 2018July 20, 2018

Immunotherapy Use Can Double Survival Rate of Melanoma Patients with Brain Metastasis, Large Study Reports

News

Melanoma patients with brain metastasis have seen significant improvements in their survival rates since immune checkpoint inhibitors like Yervoy (ipilimumab) came into treatment use, a study based on “real-life” ... Read more

July 10, 2018July 10, 2018

Study Will Test CAR T-cell Immunotherapy in Young People with Brain, Spinal Cord Tumors

News

The Seattle Children’s Hospital is conducting a pioneering clinical trial testing engineered immune cells as a treatment for children and young adults with a kind of brain cancer that produces ... Read more

June 8, 2018

Immunotherapy Targeting Tumor Mutations Leads to Complete Response in Advanced Breast Cancer Patient, NIH Reports

News

A tweaked version of a cellular immunotherapy that recognizes mutations in a patient’s tumor has led to the complete regression of metastatic breast cancer in a woman whose disease ... Read more

May 4, 2018

Advanced Melanoma Patients Seen to Respond to CMP-001, Keytruda Combo in Ongoing Study

News

Intratumoral injection of CMP-001 in combination with Keytruda (pembrolizumab) worked to reduce tumor burden in advanced melanoma patients whose disease failed to respond, or progressed, when treated with PD-1 inhibitors, ... Read more

April 24, 2018April 24, 2018

CAR T-cell Therapy at Higher Dose Might Treat Advanced Neuroblastoma, Early Trial Results Suggest

News

At higher doses, an immunotherapy approach using chimeric antigen receptor (CAR) T-cells may help to treat advanced neuroblastoma, a rare cancer that mostly affects babies and young children, according to ... Read more

April 6, 2018April 6, 2018

Five Prime Doses First Patient With Investigational Antibody FPA150

News

The Phase 1 clinical trial testing FPA150, an investigational antibody targeting the B7-H4 protein, in patients with solid tumors has dosed its first participant, Five Prime Therapeutics announced. Patients eligible for ... Read more

April 3, 2018April 3, 2018

New Technology that Takes ‘Instagram’ of Immune System May Open Door for Precision Cancer Therapies

News

A new technology that creates a sort of “Instagram” of the immune system may help predict a patient’s response to cancer immunotherapies, researchers say. “What I use here is ... Read more

March 12, 2018March 12, 2018

Phase 3 Trial of Idera’s IMO-2125 Combo Therapy Is Recruiting Advanced Melanoma Patients

News

A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s experimental immunotherapy, IMO-2125, in combination ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

New UNC Software Aims to Make Stem Cell Transplants Safer for Leukemia Patients

FDA Approves Opdivo for Certain Patients with Advanced Non-Small Cell Lung Cancer

Immunotherapy Use Can Double Survival Rate of Melanoma Patients with Brain Metastasis, Large Study Reports

Study Will Test CAR T-cell Immunotherapy in Young People with Brain, Spinal Cord Tumors

Immunotherapy Targeting Tumor Mutations Leads to Complete Response in Advanced Breast Cancer Patient, NIH Reports

Advanced Melanoma Patients Seen to Respond to CMP-001, Keytruda Combo in Ongoing Study

CAR T-cell Therapy at Higher Dose Might Treat Advanced Neuroblastoma, Early Trial Results Suggest

Five Prime Doses First Patient With Investigational Antibody FPA150

New Technology that Takes ‘Instagram’ of Immune System May Open Door for Precision Cancer Therapies

Phase 3 Trial of Idera’s IMO-2125 Combo Therapy Is Recruiting Advanced Melanoma Patients

Pin It on Pinterest